drugset
drugset / Trial / NCT05804227

Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Gliomas

NCT05804227 ↗

Phase 0 Recruiting 40 enrolled M.D. Anderson Cancer Center BioMed Valley Discoveries, Inc · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

To learn if the study drug, ulixertinib, can cross over the blood-brain barrier in patients with recurrent brain tumors

Timeline

Start
2023-04-20
Primary completion
2027-09-22
Completion
2027-09-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Ulixertinib Small molecule — Oral

Indications

glioma